+(91) 79 4891 1722



Fulvestrant is a drug treatment ofhormone receptor-positive metastatic breast cancer in postmenopausal women withdisease progression following anti-estrogen therapy. It is a complete estrogenreceptor antagonist with no agonist effects, which in addition, accelerates theproteasomal degradation of the estrogen receptor.

Ralington pharma LLP (India), a globalmanufacturer and supplier for Prodx for R&D, Pilot or Commercials  Quantities with Pharmacopeial Grade USP/ EP/ BP/ IP/ JP/ In-House.

Prodx available with USDMF,EDMF, DMF, USFDA, EUGMP, GMP, ISOCERTIFIED,WHO-GMP and DMF as per the requirement. Product supply inStandard Packaging & labeling as per FDA along with supportivedocumentation. We can also offer Intermediates of  prodx.

ProductType : API
Molecular Formula : C32H47F5O3S
CASNo : 129453-61-8
Molecular Weight : 606.77
Synonym : (7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol,,,

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).